Trending Up0.0191 (3.1317%)
  • Bid / Lots
    0.6002/ 12
  • Ask / Lots
    0.6800/ 8
  • Open / Previous Close
    0.6077 / 0.6099
  • Day Range
    Low 0.5953
    High 0.6340
  • 52 Week Range
    Low 0.3377
    High 1.6500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.6099
09:32 ET5190.6077
09:33 ET5000.605001
10:00 ET11150.595261
10:02 ET1000.62
10:20 ET128140.6288
10:22 ET3500.6288
10:24 ET1000.6288
10:51 ET1000.624335
10:56 ET3180.6288
10:58 ET1000.6288
11:03 ET15000.6144
11:05 ET2000.6288
11:20 ET9550.6287
11:21 ET2000.6288
11:30 ET11000.6288
11:36 ET2500.6
11:38 ET1000.6288
11:48 ET1660.614399
11:54 ET2000.628699
12:01 ET20000.6288
12:03 ET7500.6288
12:17 ET4620.6288
12:39 ET3940.614401
12:42 ET1000.6288
01:00 ET6000.6288
01:09 ET1140.6288
01:18 ET1050.61005
01:31 ET36000.628
02:02 ET4740.6311
02:12 ET26900.6123
02:14 ET5000.63
02:16 ET2300.634
02:20 ET4000.6123
02:27 ET8500.6123
02:30 ET2000.608
02:57 ET1000.608
03:26 ET5000.633
03:30 ET5000.629
03:39 ET2000.63
03:48 ET20770.63
03:50 ET52000.63
03:51 ET13990.63
03:53 ET1000.63
03:57 ET2000.6246
04:00 ET48850.629
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMBRX
Moleculin Biotech Inc
United StatesCOEP
Coeptis Therapeutics Holdings Inc
United StatesPMCB
PharmaCyte Biotech Inc
United StatesETST
Earth Science Tech Inc
United StatesSEEL
Seelos Therapeutics Inc
United StatesCHHE
China Health Industries Holdings Inc
As of 2024-02-29

Company Information

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. Annamycin is in development for the treatment of refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Contact Information

5300 Memorial Dr Ste 950HOUSTON, TX, United States 77007-8274


Chairman of the Board, President, Chief Executive Officer
Walter Klemp
Chief Financial Officer, Executive Vice President
Jonathan Foster
Chief Scientific Officer
Donald Picker
Senior Chief Medical Officer
Paul Waymack
Independent Director
Michael Cannon

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.